Corcept Therapeutics Misses Q1 Targets, Stock Still Optimistic

Corcept Therapeutics Q1 2026 revenue missed expectations, with sales up 4.9% to $164.9M but short of the $186M forecast. Earnings per share showed a $0.30 loss, worse than the $0.14 expected. Adjusted operating income plummeted to -$49.6M, missing estimates by a wide margin. Despite strong revenue growth over the past five years, expenses have squeezed margins hard. The companys stock popped 1.7% to $47.44 after the guidance lift for full-year revenue, which hits $1B at the midpoint, 7.2% above analysts estimates. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1bc8302f3477ddf6